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Mammals are composed of hundreds of different cell types with specialized functions.
Each of these cellular phenotypes are controlled by different combinations of
transcription factors. Using a human non islet cell insulinoma cell line (TC-YIK) which
expresses insulin and the majority of known pancreatic beta cell specific genes
as an example, we describe a general approach to identify key cell-type-specific
transcription factors (TFs) and their direct and indirect targets. By ranking all human
TFs by their level of enriched expression in TC-YIK relative to a broad collection
of samples (FANTOM5), we confirmed known key regulators of pancreatic function
and development. Systematic siRNA mediated perturbation of these TFs followed by
qRT-PCR revealed their interconnections with NEUROD1 at the top of the regulation
hierarchy and its depletion drastically reducing insulin levels. For 15 of the TF knock-
downs (KD), we then used Cap Analysis of Gene Expression (CAGE) to identify
thousands of their targets genome-wide (KD-CAGE). The data confirm NEUROD1 as
a key positive regulator in the transcriptional regulatory network (TRN), and ISL1, and
PROX1 as antagonists. As a complimentary approach we used ChIP-seq on four of
these factors to identify NEUROD1, LMX1A, PAX6, and RFX6 binding sites in the
human genome. Examining the overlap between genes perturbed in the KD-CAGE
experiments and genes with a ChIP-seq peak within 50 kb of their promoter, we
identified direct transcriptional targets of these TFs. Integration of KD-CAGE and ChIP-
seq data shows that both NEUROD1 and LMX1A work as the main transcriptional
activators. In the core TRN (i.e., TF-TF only), NEUROD1 directly transcriptionally
activates the pancreatic TFs HSF4, INSM1, MLXIPL, MYT1, NKX6-3, ONECUT2, PAX4,
PROX1, RFX6, ST18, DACH1, and SHOX2, while LMX1A directly transcriptionally
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activates DACH1, SHOX2, PAX6, and PDX1. Analysis of these complementary datasets
suggests the need for caution in interpreting ChIP-seq datasets. (1) A large fraction of
binding sites are at distal enhancer sites and cannot be directly associated to their targets,
without chromatin conformation data. (2) Many peaks may be non-functional: even when
there is a peak at a promoter, the expression of the gene may not be affected in the
matching perturbation experiment.
Keywords: ChIP-seq, transcriptional regulatory network, perturbation, pancreas, CAGE, FANTOM5
INTRODUCTION
Regulation of gene expression by combinations of transcription
factors (TFs) is a fundamental process that determines cellular
identity and functions. TFs have the ability to recognize and bind
short sequence motifs throughout the genome, and, either alone
or in combination with other TFs, modulate mRNA levels in a
cell until it acquires the predetermined phenotype (Mitchell and
Tjian, 1989; Wray et al., 2003). In humans it has been estimated
that there are at least 411 different cell types (Vickaryous and
Hall, 2006) and 1500–2000 different transcription factors (Roach
et al., 2007; Vaquerizas et al., 2009; Wingender et al., 2015),
with ∼430 TFs expressed at appreciable levels in any given
primary cell type (Forrest et al., 2014). Identifying key cell type
specific transcription factors and their targets is fundamental to
understanding cellular states, and is important for regenerative
medicine where efforts are made to direct differentiation of stem
cells toward a medically relevant cell type (Cahan et al., 2014).
Over the years, multiple approaches to map the targets of TFs
have been developed. Computational approaches that predict TF
targets based upon their co-expression with a given TF and/or
the presence of a transcription factor binding site motif (TFBS)
in their promoter regions have helped to identify direct targets
(Wasserman and Sandelin, 2004; Tompa et al., 2005; Valouev
et al., 2008; FANTOM Consortium et al., 2009); however, these
are purely predictive methods and the validation rate, when
experimental validations are carried out, is low. Motif prediction
methods are limited as the vast majority of our TFs have no
well-defined TFBS, and TFs from the same family bind very
similar motifs. Even for those cases where a motif is known,
the information content is so low that the majority of binding
site predictions will likely be false positives (Wasserman and
Sandelin, 2004). Lastly, unless the expression levels of the TFs
themselves are taken into consideration, inaccurate predictions
can be made where a binding event may be predicted as
important despite the fact that the corresponding TF is not even
present in the cell.
Alternatively, TF targets can be identified experimentally.
Experimental perturbation of TFs (Hilger-Eversheim et al., 2000)
followed by expression profiling can identify global sets of genes
affected by the given TF. This is a powerful approach, but does
not discriminate direct from indirect targets (genes regulated
by TFs which are regulated by the perturbed TF). Another
experimental approach directly determines physical binding sites
in the genome using protocols such as ChIP-CHIP, DamID or
ChIP-seq (van Steensel and Henikoff, 2000; Horak et al., 2002;
Robertson et al., 2007). The caveat with these methods lies in
that they do not distinguish functional from non-functional
binding. By combining the perturbation and physical interaction
approaches we can overcome the limitations of each.
The remaining issue, however, is the scale of the problem. TF-
target interactions vary between cell types as there are different
combinations of transcription factors expressed and different
chromatin configurations in each cell type. Thus, ultimately, what
we need is a compendium of cell type specific regulatory networks
for every cell type that makes up the human body. Given its
scale, the problem necessitates prioritization of the cell type to be
studied and the sets of TFs considered. We need ways to identify
which TFs are most important to a given cell type.
Recently, the FANTOM5 project used single molecule
sequencing to generate CAGE (Kanamori-Katayama et al., 2011)
across a large collection of human and mouse primary cells, cell
lines and tissue samples, providing a nearly comprehensive set
of human and mouse, promoter and enhancer regions and their
expression profiles (Andersson et al., 2014; Forrest et al., 2014).
Importantly, for the prioritization of key TFs, the FANTOM5
CAGE data boasts expression profiles for 94% (1665/1762) of
human TFs; this can be used to generate cell-type-specific ranked
lists (expression relative to median across almost 1000 samples).
What emerged from those lists is that the TFs with the most
enriched expression in a given primary cell type often had
phenotypes relevant to that cell type [e.g., mutations of osteoblast
enriched TFs resulted in bone phenotypes, hematopoietic stem
cell enriched TFs in blood phenotypes and inner ear hair cell
enriched TFs in deafness (Forrest et al., 2014)]. These enriched
TFs are therefore likely key components of cell-type-specific
transcriptional regulatory networks (TRNs). To probe cell type
enriched TFs in more detail, we explored an integrated approach
for dissecting TRNs using siRNA knock-down, qRT-PCR, CAGE
(Shiraki et al., 2003), and ChIP-seq (Robertson et al., 2007).
The large numbers of cells required for our systematic studies
made it necessary to find an easily expandable cell line. Reviewing
the FANTOM5 expression profiles, we chose an interesting
cell line, TC-YIK (Ichimura et al., 1991), derived from an
argyrophilic small cell carcinoma (ASCC) of the uterine cervix,
which expresses insulin and showed enriched expression for
dozens of pancreatic transcription factors. We show that TC-
YIK cells express 75% of a set of genes previously reported as
islet cell specific and 85% of a set of genes previously reported as
beta cell specific. Given the difficulty in obtaining primary human
beta cells for research, our results may be of interest to studying
pancreatic transcriptional regulation, with the caveat that we
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are only using TC-YIK as an experimentally tractable cell line
model to examine the prediction of key TFs; it is a non-islet-cell
insulinoma and therefore the regulatory edges inferred here may
not generalize to primary islet cells.
Using newly created genome-wide datasets on TC-YIK
enriched TFs, and a comparative set of non-enriched TFs, we
sought to determine the importance of each factor inmaintaining
the TC-YIK cell state. Knock-down followed by CAGE profiling
allowed us to identify, genome-wide, the set of genes affected by
each TF, while integration with ChIP-seq data on the same factors
allowed us to further discriminate direct from indirect TF targets.
We present the results of the TC-YIK analysis and show that the
combination of CAGE and ChIP-seq on key TFs is a powerful
approach for studying mammalian transcriptional networks and
necessary for dissection of direct and indirect edges. An overview
of the datasets used, our analysis and the main findings are
summarized in the workflow shown in Figure 1.
This work is part of the FANTOM5 project. Data download,
genomic tools and co-published manuscripts have been
summarized at http://fantom.gsc.riken.jp/5/.
RESULTS
The TC-YIK Cell Line Expresses Pancreatic
Islet Cell Transcripts
Previously, TC-YIK cells were shown to generate neurosecretory
granules and express chromogranin A (CHGA) and gastrin
(GAST; Ichimura et al., 1991). A systematic review of endocrine
hormones and peptides detected in TC-YIK confirmed CHGA
and GAST were expressed at high levels and revealed also
expression of insulin (INS), ghrelin (GHRL), and transthyretin
(TTR; Table 1). All of these proteins [insulin, gastrin (GAST;
Wang et al., 1993; Rooman et al., 2002; Téllez et al., 2011),
FIGURE 1 | Diagram showing the workflow of the analyses. (A) The FANTOM5 data reveal the TC-YIK cell line expresses key pancreatic neuropeptides and
pancreatic transcription factors. (B) New data is generated for this study including siRNA perturbation of TC-YIK enriched and non-enriched TFs. siRNA perturbed
samples are profiled by qRTPCR in a matrix RNAi design and by CAGE to globally identify target promoters. ChIP-seq on 4 key TFs is also carried out to identify
genome wide binding sites. (C) KD-CAGE and ChIP-seq data are integrated to identify directly regulated targets of NEUROD1 and LMX1A.
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TABLE 1 | Neurosecretory peptide expression in TC-YIK.
Gene Expression in FANTOM5 (TPM)
TC-YIK Rank (out of Max Sample expressing highest
988 samples) level of peptide
CHGA 6062.51 1 6062.51 TC-YIK
TTR 1202.73 21 60441.3 medulla oblongata, adult
GAST 1096.66 1 1096.66 TC-YIK
INS 50.13 4 5119.98 Duodenum, fetal
GHRL 15.37 5 54.13 Eosinophils
SST 7.81 93 3612.79 Duodenum, fetal
IAPP 0 NA 26.58 Pancreas, adult
GCG 0 NA 3534.95 Gastric cancer cell line AZ521
ghrelin [(GHRL; Date et al., 2002; Wang et al., 2008; Arnes
et al., 2012), transthyretin (TTR; Refai et al., 2005; Su et al.,
2012), and chromogranin A (CHGA, a precursor of pancreatic
chromostatin; Cetin et al., 1993)] play key roles in the pancreas
(Table 1). In contrast to insulin, which is a biomarker for
pancreatic beta cells, somatostatin (SST), glucagon (GCG), and
islet amyloid polypeptide (IAPP), the biomarkers for pancreatic
delta, alpha, and gamma cells, respectively, were lowly expressed
or absent in TC-YIK cells. We next examined the expression of
genes described in the beta cell gene atlas (Kutlu et al., 2009) as
being specifically expressed in human islets. We find that 75% of
the 938 human islet tissue specific genes reported by the authors
are detected in TC-YIK [Supplementary Table 1, ≥ 5 tags per
million (TPM)]. The authors provide a further subset of 445
genes that are enriched in alpha and/or beta cells and overlap the
islet specific list (76 are expressed > 2-fold higher in alpha cells
and 153 are expressed > 2-fold higher in beta cells). In TC-YIK,
we find that 65% of these alpha cell enriched genes and 85% of the
beta cell enriched genes are detected (Supplementary Table 2, ≥
5 TPM). From this review we conclude that, although TC-YIK
does not completely recapitulate the beta cell transcriptome, it
shares significant similarity to islet cells. For this reason TC-YIK
is sufficiently interesting for the purposes of an investigative study
integrating CAGE and ChIP-seq data. Lastly, although there are
rare reports of non-islet-cell insulinomas that ectopically express
insulin [e.g., kidney (Ramkumar et al., 2014), liver (Furrer et al.,
2001), brain (Nakamura et al., 2001)] and additional cases of
argyrophilic small cell carcinoma (ASCC) of cervix (Kiang et al.,
1973; Seckl et al., 1999), ours is the first report to our knowledge
that identifies a non-islet-cell line (TC-YIK) where the majority
of the beta cell program is active.
Pancreatic Transcription Factors are
Enriched in TC-YIK cells
To identify TC-YIK-enriched-transcription factors, we ranked
all 1665 human TFs according to their expression in TC-YIK
cells relative to the median expression across the 988 human
samples in the FANTOM5 phase 1 collection (Forrest et al., 2014).
The highest ranked TF was NEUROD1, a factor known to be
key in the differentiation of beta cells and insulin production
(Itkin-Ansari et al., 2005; Guo et al., 2012). Furthermore, of
the 42 most TC-YIK enriched TFs (enrichment score > 1.25,
∼18-fold enrichment over median expression levels), 33 were
previously implicated in pancreatic biology, including direct
regulators of insulin (Sander and German, 1997), key factors
for islet cell development (Wang et al., 2005; Guo et al., 2011),
genes associated with diabetes (Foti et al., 2005) and with
pancreatic endocrine tumors (Johansson et al., 2008; Table 2,
Supplementary Table 3).
CAGE profiling of themouse orthologs throughout pancreatic
development (also profiled in FANTOM5) detected 33 of the 42
TFs in at least one stage with most changing expression levels
over time (Supplementary Figure 1). This added support for a
further seven of the remaining nine TFs enriched in TC-YIK
(ASCL2, HLF, HSF4, IRF6, IRF8, MYRF, and NPAS3) as likely
important factors in pancreatic development.
Assessing the Interconnection of Key TFs
A key question is whether the cell type enriched TFs identified
in FANTOM5 are key regulators of the cellular state and
whether these enriched factors are more (or less) important than
housekeeping TFs that are more broadly expressed. Logic would
suggest that those TFs expressed in an enriched manner are more
likely to be regulated by other enriched TFs, and that their targets
are also more likely to be enriched. To test our assumption, we
first carried out siRNA perturbation of a set of enriched and
non-enriched (but expressed) TFs in TC-YIK cells and assessed
their effect on expression of enriched and non-enriched targets
by qRT-PCR.
Multiple siRNAs were tested for each enriched factor and
the one with the best efficiency was kept; siRNAs for 26 TFs
reduced expression below 50%, a further 7 suboptimal siRNAs
reduced expression to 51–77% of that of the scrambled control,
while for the remaining TFs we were unable to find an efficient
siRNA (Supplementary Table 4). An additional 8 non-enriched
TFs were also perturbed below 50% (Table 2). After perturbation,
RNA was extracted and qRT-PCR was used to measure the
knock-down response in a 41× 52 matrix of expression changes,
where 41 columns represent the TFs that were perturbed and
52 rows represent the measured qRT-PCR values of target
genes after perturbation (Supplementary Table 5). Experiments
were carried out in triplicate and knock-down was assessed
relative to a scrambled siRNA sequence. Of the ∼2000 potential
(TF-target) edges tested, 551 were up- or down-regulated
1.5-fold or more [threshold as used in our previous studies
(Tomaru et al., 2009)].
Looking at the number of affected targets for each TF knock-
down (out degree) and the number of knock-downs that affected
each TF (in degree; summarized in Supplementary Table 6) we
identifiedNEUROD1 as a key activator at the top of the hierarchy.
NEUROD1 knock-down caused down-regulation of 21 of the
52 tested targets (the most influenced being PAX4, followed
by GHRL, INS, GAST, CHGA, GCK, RFX6, and PAX6). In an
analogous way, ISL1 was the main antagonist in the network,
where its knock-down affected 11 targets, all of which were up-
regulated (among those CHGA, LMX1A, PAX4, and NEUROD1).
Other likely key TFs, RFX6, SHOX2, PAX6, MNX1, LMX1A, and
PDX1 also strongly affected several targets.
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TABLE 2 | TFs enriched in TC-YIK and their putative function in pancreas.
TF_symbol Expression Enrichment log10 Insulin or Detected in mouse Experiments
TPM (TC-YIK+1/median+1) pancreatic biology? developing pancreas
TRANSCRIPTION FACTORS WITH ENRICHED EXPRESSION IN TC-YIK CELLS
NEUROD1 593 2.77 Yes Yes Si, CA, CS
INSM1 519 2.72 Yes Yes –
PAX6 296 2.47 Yes Yes Si, CA, CS
NKX6-3 239 2.38 Yes No –
ARX 237 2.38 Yes Yes Si
MLXIPL 218 2.34 Yes Yes Si, CA
RFX6 146 2.17 Yes Yes Si, CA, CS
ONECUT2 151 2.14 Yes Yes Si, CA
PAX4 133 2.13 Yes Yes Si, CA
PDX1 127 2.11 Yes Yes Si
DACH1 269 2.05 Yes Yes Si, CA
ISL1 102 2.01 Yes Yes Si, CA, CS
FEV 94 1.98 Yes No Si
HOPX 168 1.95 Yes Yes Si, CA
FOXA2 88 1.95 Yes Yes Si
ST18 78 1.90 Yes Yes –
HNF4G 75 1.88 Yes Yes –
PROX1 106 1.84 Yes Yes Si, CA
HNF4A 69 1.84 Yes Yes Si
ELF3 51 1.71 Yes Yes Si
SHOX2 62 1.70 Yes No Si, CA
NPAS3 55 1.63 No Yes –
CDX2 41 1.63 Yes Yes –
HOXA10 40 1.61 Yes No Si
MNX1 38 1.59 Yes Yes Si, CA
ASCL2 34 1.54 No Yes –
TFAP2A 97 1.53 Yes No –
IRF8 31 1.51 No Yes Si
CASZ1 70 1.51 Yes Yes –
SIX3 30 1.49 No No Si
C11orf9/MYRF 62 1.49 No Yes –
MYT1 26 1.43 Yes Yes Si
HOXB13 26 1.43 Yes No Si
ASCL1 25 1.42 Yes Yes Si, CA
NR0B2 24 1.41 Yes Yes Si
LMX1A 24 1.40 Yes No Si, CA, CS
HSF4 27 1.33 No Yes –
HES6 71 1.32 Yes Yes –
HLF 23 1.31 No Yes Si
IRF6 23 1.30 No Yes –
DLX6 19 1.29 No No Si
GATA4 18 1.28 Yes Yes Si, CA
UBIQUITOUS TRANSCRIPTION FACTORS EXPRESSED IN TC-YIK BUT NOT ENRICHED
ATF5 290 0.73 No Yes Si, CA
HMGB2 243 0.37 No Yes Si, CA
GTF3A 213 0.36 No Yes Si, CA
HMGA1 672 0.34 Yes Yes Si, CA
(Continued)
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TABLE 2 | Continued
TBP 29 0.15 No Yes Si, CA
TAF9 80 0.09 No Yes Si, CA
TCF25 90 −0.10 No Yes Si, CA
TAF10 75 −0.33 No Yes Si, CA
An extended version of the table is provided as Supplementary Table 3 with references to pancreatic biology. Experiments used in this paper (Si, siRNA perturbation; CA, cap analysis
of gene expression; CS, ChIP-seq). TC-YIK enriched factors that were not tested by siRNA were excluded due to oligo design or knock-down efficiency problems.
FIGURE 2 | Influence of transcription factor knock-down on INS expression. Log2 expression fold changes for INS gene upon siRNA perturbation of 41 TFs.
NEUROD1 knock-down caused the most down–regulation of insulin expression, while highest up-regulation was observed in TBP knock-down. Error bars indicate
standard deviation over triplicate measurements. TFs in bold indicate those that were TC-YIK-enriched rather than ubiquitous.
Of note, knock-down of 28 of the 33 TFs enriched in TC-
YIK and 7 of the 8 non-enriched TFs affected insulin expression
levels, with the enriched factors NEUROD1, DACH1, RFX6, and
the non-enriched TFs HMGB2, GTF3A, and HMGA1 knock-
down causing the greatest decreases in insulin transcript levels
(Figure 2). Interestingly, knock-down of the non-enriched TF
TATA binding protein (TBP) led to the highest increase in insulin
transcript, which may indicate a shift in the balance between
TATA dependent and TATA independent transcription.
Identifying Genome-wide TF Targets using
Knock-down and Cage
The above section focused on a limited and biased set of
52 target transcripts. We next applied CAGE [KD-CAGE;
(Vitezic et al., 2010)] to identify genome-wide the sets of
promoters that were perturbed after knock-down of 15 of
the enriched TFs and all 8 non-enriched TFs using the same
RNA samples as used in the qRT-PCR. Notably the fold
changes observed by CAGE and qRT-PCR were highly correlated
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FIGURE 3 | KD-CAGE analysis. (A) Up-regulated and down-regulated TSSs in KD-CAGE experiments. Bars indicate, the numbers of up-regulated, and
down-regulated TSSs detected by edgeR (p < 0.05) after siRNA knockdown of each factor. Line indicates the log transformed ratio of up-regulated to down-regulated
TSS (e.g., note NEUROD1 causes a much larger number of down-regulated TSS than up-regulated ones, while MNX1 shows the reverse). (B) Fractions of up or
down-regulated promoters that are TC-YIK-enriched or non-enriched. (C) Comparison of the ratios of TC-YIK-enriched to non-enriched promoters for up and
down-regulated TSS sets. Note, ISL1 and PROX1 appear antagonistic to the TC-YIK state. (D) Diagram summarizing the results of the state enrichment and gene
ontology enrichment analyses. *Indicates at least 15% of the up or down-regulated promoters were TC-YIK enriched.
(Supplementary Figure 2), indicating the suitability of CAGE
for this experiment.
Promoters specifically affected by the TF knock-downs
in comparison to scrambled siRNA control samples
were then identified using edgeR (Robinson et al., 2010;
Supplementary Table 7). Similar numbers of affected promoters
were detected for enriched and non-enriched TFs; between 8229
and 19,467 and between 9922 and 18,362 promoters respectively
(Supplementary Table 8). For six of the TF knock-downs
(HMGA1, NEUROD1, LMX1A, SHOX2, NROB2, GATA4,
RFX6), there were at least twice as many down-regulated
promoters as up-regulated ones, suggesting that these factors
work as activators. Conversely, for knock-down of MNX1 and
TBP we observed at least twice as many up-regulated promoters
as down-regulated ones, suggesting they work as repressors
(Figure 3A).
Identifying TFs Important for Maintaining
Cell State
To understand which TFs are responsible for maintaining the
TC-YIK cell state, we next identified a set of 4639 promoters
with enriched expression (>3-fold) in TC-YIK compared to
median expression in FANTOM5. We refer to this set as
TC-YIK-enriched-promoters, and to the remainder as non-
enriched-promoters. We then used these sets to separate TFs
into synergists or antagonists to the cell fate: if perturbation of
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a TF causes down-regulation of a significantly larger fraction
of TC-YIK-enriched-promoters than non-enriched-promoters,
then this would suggest that the factor in question is important
for maintaining the TC-YIK state (pro-TC-YIK); similarly, if the
perturbation led to up-regulation of a significantly larger fraction
of TC-YIK-enriched-promoters than non-enriched-promoters,
this would suggest that the factor antagonizes the TC-YIK state
(anti-TC-YIK).
Starting from the assumption that TC-YIK state is maintained
by regulation of TC-YIK-enriched-promoters, we checked, for
each TF knock-down, whether TC-YIK-enriched-promoters
were more likely to be affected (either up- or down- regulated)
compared to a random event. Knock-down of all factors
resulted in significantly more TC-YIK-enriched-promoters being
perturbed (in either direction) than expected (hypergeometric
probability test, Supplementary Table 8), and testing the up-
and down-regulated sets separately also showed that for all
perturbations significantly more TC-YIK-enriched-promoters
were up-regulated and significantly more TC-YIK-enriched-
promoters were down-regulated than expected by chance. This
suggests that all tested TFs contribute to some extent to
the maintenance of the TC-YIK state (Supplementary Table 8,
Figure 3B).
Of particular note, NEUROD1 knock-down led to down-
regulation of 50% of the TC-YIK-enriched-promoters, and ISL1
knock-down led to up-regulation of the most TC-YIK-enriched-
promoters compared to the other factors, suggesting that they
are pro- and anti-TC-YIK factors respectively (Figure 3B).
To examine this in more detail we calculated the ratios of
TC-YIK-enriched-promoters to non-enriched-promoters in the
up-regulated sets over the down-regulated sets. High ratios
correspond to anti-TC-YIK TFs and low ratios correspond
to pro-TC-YIK TFs (Figure 3C). To compare these ratios
systematically we used Chi-square with Yates correction to test
for significant differences (Supplementary Table 8).
Using the above mentioned metric the TC-YIK-enriched
factors MNX1, NEUROD1, SHOX2, PAX4, NROB2, HOPX,
RFX6, MLXIPL, GATA4, LMX1A, PAX6, ASCL1 and the non-
enriched factors ATF5, TAF10, HMGA1, TCF25, TAF9, HMGB2,
GTF3A all appear to be pro-TC-YIK (Figure 3C). In the case of
ISL1 and PROX1 the ratios are shifted in the opposite direction
with a higher fraction of up-regulated TC-YIK-enriched-
promoters compared to non-enriched-promoters, indicating
they act as antagonists to the TC-YIK state (Figure 3C).
Interestingly, MNX1 knock-down led to up-regulation of many
non-enriched-promoters (10,483 up vs. 4426 down, ratio= 2.37),
and relatively few TC-YIK-enriched-promoters (821 up vs. 1453
down, ratio = 0.57). Thus, MNX1 is pro-TC-YIK but appears to
do this by actively repressing non-enriched-promoters.
TC-YIK TFs Regulate Pancreatic Genes
Many GO terms were significantly enriched in the up- and
down-regulated gene sets, including terms related to pancreatic
development and function (Supplementary Table 9). In
particular, the following down-regulated gene sets were enriched
for the terms “pancreas development” (ATF5,MNX1, NEUROD1,
PAX4, RFX6, SHOX2, TAF9), “insulin secretion” (ATF5, GATA4,
HOPX, LMX1A, MLXIPL, MNX1, NEUROD1, NROB2, PAX6,
RFX6, SHOX2, TAF10, TAF9, TBP), “cellular response to insulin
stimulus” (ATF5, GATA4, LMX1A,MLXIPL, NEUROD1, NROB2,
PAX4, PAX6, RFX6, TAF9, TCF25), “glycogen biosynthetic
process” (ATF5, HOPX, LMX1A, MNX1, NEUROD1, NROB2),
glycogen catabolic process (GTF3A, NROB2, SHOX2), and
“glycogen metabolic process” (HOPX, NEUROD1, NROB2).
While, for the upregulated gene lists, ISL1 appears to be an
antagonist to the pancreatic program with its knockdown
leading to up-regulation of a gene set enriched for the terms
“glucose homeostasis,” “pancreas development,” “regulation
of glucose metabolic process,” “insulin secretion,” “endocrine
pancreas development,” “endocrine system development,” and
“peptide hormone secretion” (Supplementary Table 9).
In summary, it appears that both enriched and non-enriched
factors contribute to the TC-YIK TRN and that, intriguingly,
despite ISL1 and PROX1 both being enriched in TC-YIK, they
seem to be antagonists to the system (Figure 3D).
Protein-DNA Edge Mapping by ChIP-seq of
NEUROD1, LMX1A, RFX6, and PAX6
As the perturbation edges identified above could be either direct
or indirect, we next used ChIP-seq data for four of the TC-
YIK enriched factors to generate a paired complimentary dataset
which would identify the genomic binding sites of the same
factor. Integration of these two edge types (KD-CAGE and
ChIP-seq) should allow us to discriminate direct from indirect
edges. Biological duplicates for each factor were generated and
ChIP-seq binding peaks were called relative to input chromatin
using MACS (Zhang et al., 2008). We note that the number of
peaks called for the same target in different biological replicates
varied (NEUROD1: 7195 and 14,949 peaks, LMX1A: 7622 and
7361 peaks, PAX6: 587 and 7866 peaks, RFX6: 960 and 1659
peaks). To be conservative we only used peaks that were called
as reproducible with 90% likelihood using the irreproducible
discovery rate (Li et al., 2011) method (IDR≤ 0.1) which yielded
144 RFX6 peaks, 190 PAX6 peaks, 4506 NEUROD1 peaks and
2166 LMX1A peaks. Scanning these peaks for known TFBS
motifs using HOMER (Heinz et al., 2010) found significant
enrichment for the relevant motifs (NeuroD1/Homer motif
was found in 46% of NEUROD1 peaks, 7.4% of background;
Lmx1a-mouse/Jaspar–9% of LMX1A peaks, 4.7% of background;
PAX6/SwissRegulon–11% of PAX6 peaks, 2.2% of background,
Supplementary Figure 3). For RFX6 there is no known motif;
however, the motifs of other RFX family members, and in
particular RFX5, were enriched (37% of RFX6 peaks and 3% of
background). De-novo motif finding on the RFX6 ChIP-seq data
identified a novel motif that is found in 58% of RFX6 peaks and
4% of background sequences. This motif closely resembles, but is
different from, other RFX family motifs (Figure 4A).
Examining the distribution of binding in the genome, we
observed that the four factors often bound in combination at
the same sites, and seldom bound at promoters. For example
in the RERE locus we observed co-binding of NEUROD1 and
LMX1A, and NEUROD1 and RFX6, respectively, at distinct sites
(see boxes in Figure 4B). Genome wide, co-binding of two or
more of these enriched factors was common, with more than half
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FIGURE 4 | ChIP-seq analysis of NEUROD1, LMX1A, PAX6, and RFX6 in TC-YIK cells. (A) Comparison of the novel RFX6 motif to that of other RFX members.
Note that it is unlikely that the antibody used (S-15, Santa Cruz) would cross react with any other RFX family member as the antibody is raised against a peptide in the
unique extended C-terminus of the protein which is not present in any of the other RFX family members. (B) ZENBU genome browser (Severin et al., 2014) view
showing combinatorial binding of LMX1A-NEUROD1 and NEUROD1-RFX6 in the first intron of the RERE locus. Red, LMX1A; Blue, NEUROD1; Green, PAX6; Yellow,
RFX6; Gray, input chromatin. (C) Venn diagram showing the degree of overlap between the peaks called for the four factors, numbers correspond to count of peaks
overlapping by at least 1 base. (D) Comparison of the TF ChIP-seq peaks to open chromatin sites identified in human islet cell material by Pasquali et al. (2014).
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of the RFX6 and PAX6 sites overlapping a LMX1A or NEUROD1
site (Figure 4C).
Given (1) the paucity of promoter proximal binding of these
factors and (2) the ample similarity between TC-YIK cellular
program and endocrine program, we compared the binding sites
to a map of open chromatin sites in human islet cells. Pasquali
et al. (2014) integrated FAIRE-seq, and ChIP-seq of H2A.Z,
H3K4me1, H3K4me3, H3K27ac, and CTCF to classify open sites
in the genome of human islets as promoters (C1), poised/inactive
enhancers (C2), active enhancers (C3), CTCF-bound sites (C4),
and other open sites (C5). In our ChIP-seq data, we found that
between 46 and 62% of peaks overlapped at least one of these
open chromatin sites (this was comparable to the overlap seen
by the authors for their own TF ChIP-seq experiments; 48 to
81% for NKX2.2, PDX1, FOXA2, NKX6.1, andMAFB). For those
peaks overlapping the islet cell open sites, we observed enriched
binding at active enhancer sites and depletion of promoter
sites for all four factors (Figure 4D, Supplementary Table 10),
suggesting that these factors primarily work at enhancers.
In support of this observation, both NEUROD1 and PAX6
have been reported previously to bind enhancer regions
(Andersen et al., 1999; Aota et al., 2003; Scardigli et al., 2003;
Inoue et al., 2007; Babu et al., 2008), and a recent PAX6 ChIP-
seq dataset in neuroectoderm cells identified multiple PAX6
regulated enhancers, and reported that less than 2% of 16,000
PAX6 peaks are near TSS of coding genes (Bhinge et al., 2014).
In the case of RFX6 there is still little known about its functional
targets. Other RFX family members have been reported to be
bound at enhancers (Reith et al., 1994; Maijgren et al., 2004;
Creyghton et al., 2010; Watts et al., 2011), and in the Pasquali
et al. study an RFX motif was over-represented at islet cell
enhancer clusters (Pasquali et al., 2014). Intriguingly, RFX6
had twice as many peaks overlapping class C5 than expected,
suggesting that RFX binding may be one of the earliest events
at opening of sites (Niesen et al., 2005). For LMX1A, ours is the
first report of its involvement at enhancers.
Integration of ChIP-seq and KD-CAGE
Data to Identify Direct Transcriptional
Targets of TFs
By combining KD-CAGE with ChIP-seq data for LMX1A,
NEUROD1, PAX6, and RFX6, we hoped to identify directly
regulated promoters (that is, promoters perturbed in the knock-
down experiments that also had matching nearby ChIP-seq
signal). In the case of NEUROD1 and LMX1A, we observed
that promoters closest to a matching ChIP-seq peak were indeed
affected. In particular for NEUROD1, almost 80% of promoters
within 1 kb of a NeuroD1 ChIP-seq peak were down-regulated
and for LMX1A almost 70% of promoters within 1 kb of an
Lmx1a ChIP-seq peak were down-regulated (Figure 5A). Both
cases indicate that these factors work primarily as transcriptional
activators. As one moves further away from a ChIP-seq peak
the fraction of down-regulated promoters drops, however, even
at distances greater than 5 kb (up to 100 kb) from a TSS we
observed a higher proportion of down-regulated TSS compared
to that seen for those >100 kb away, suggesting that both factors
can affect gene expression in cis from neighboring enhancer
elements (the closer the element, the higher the probability of
being affected). Repeating the analysis only using peaks with
or without a TFBS motif showed no significant differences
in the fractions of TSS likely to be affected. In fact, for the
case of LMX1A and NEUROD1 the fraction of perturbed TSS
increased at shorter distances relative to a ChIP-seq peak,
regardless of whether the ChIP-seq peak overlapped a motif or
not (Supplementary Table 11). In the case of RFX6 and PAX6,
we observed no such distance-dependent effect, suggesting that
either these factors work predominantly via distal sites or that the
small number of ChIP-seq peaks observed for these two factors
confounded the analysis.
Finally it is worth noting that not all proximal sites appear
to be functional. For NEUROD1 and LMX1A respectively,
17 and 18% of the TSSs within 1 kb of a ChIP-seq peak
for the same factor were unaffected in the knock-down. An
example is shown for the EYS locus. ChIP-seq and TFBS
predictions support binding of LMX1A and NEUROD1 at the
EYS promoter, but only NEUROD1 perturbation affected EYS
expression levels (Figure 5B; other examples are shown in
Supplementary Figure 4).
Role of NEUROD1 and LMX1A in the
TC-YIK TRN
Our original objective had been to integrate KD-CAGE and
ChIP-seq to identify directly regulated targets (in this case of
NEUROD1, LMX1A, PAX6, and RFX6). However, based on
the results above, we conclude that the majority of binding
events happen at enhancers, and only in the case of NEUROD1
and LMX1A where we observed enrichment for perturbed TSS
at shorter distances to the TSS can we infer direct promoter
mediated edges. For these two factors, we considered TSS that
are down-regulated at least 1.5-fold and with a ChIP-seq peak
at a distance of less than 50 kb as likely direct targets. This
identified 317 and 1543 directly regulated promoters for LMX1A
and NEUROD1 respectively (Supplementary Table 12). Finally,
to understand the hierarchy of these factors we checked whether
they directly regulate any of the other TC-YIK enriched TFs
identified in the beginning of the paper. Focusing on the core
network (TF-TF) we find that both NEUROD1 and LMX1A
directly target 12 and 4 TC-YIK enriched TFs, respectively, but
do not directly regulate each other (Figure 5C).
CONCLUSION
In this paper we have introduced an experimental strategy to
elucidate cell type specific transcriptional regulatory networks.
We start by identifying cell type enriched transcription factors
(pre-computed lists for all primary cell types available online
from the FANTOM web resource (Lizio et al., 2015) http://
fantom.gsc.riken.jp/5/) and then use a combination of siRNA
perturbation, CAGE and ChIP-seq to identify their direct
and indirect targets. This strategy leverages the strengths of
both approaches. Application of CAGE to siRNA perturbed
samples identifies affected genes and ChIP-seq identifies directly
bound targets. We show that ChIP-seq alone is insufficient
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FIGURE 5 | Integration of KD-CAGE and ChIP-seq to identify direct edges. (A) Bar graph showing the fractions of up-regulated (orange), down-regulated
(blue), and unaffected (gray) TSS in the knock-down of NEUROD1 or LMX1A. Bars correspond to different distance bins from a ChIP-seq peak for the same factor. (B)
Example of putative non-functional binding of LMX1A at the EYS locus. Note the presence of multiple NEUROD1 and LMX1A ChIP-seq peaks and relevant motifs, but
only the NEUROD1 knock-down affected EYS expression (more examples shown in Supplementary Figure 4). (C) Diagram showing TC-YIK enriched transcription
factors (from Supplementary Table 4) that are directly regulated by NEUROD1 or LMX1A. To be called a direct target, we require at least one TSS of the target gene
to be down-regulated 1.5-fold with a p-value of 0.05 and it must be within 50 kb of a ChIP-seq peak for the same factor.
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to discriminate functional from non-functional bound sites,
while perturbation approaches alone cannot unequivocally
discriminate direct from indirect targets. It is important to
precise that we are not questioning the power of ChIP methods
in identifying direct and indirect binding (Gordan et al., 2009);
the novelty of our approach lies in demonstrating that even
in the presence of a TF-DNA interaction, regulation of target
genes can happen only if the site of interaction is functional.
This work highlights an important and yet undervalued matter,
as in many previous publications researchers have assumed the
nearest gene to, or any gene within a fixed distance of, a ChIP-
seq peak, is a direct target (Shin et al., 2009; Bottomly et al.,
2010; Tallack et al., 2010; Schodel et al., 2011). This is clearly
an oversimplification. We have shown that almost a fifth of
TSS within 1 kb of a NEUROD1 or LMX1A ChIP-seq peak are
unaffected in matching siRNA knock-down. This could mean
that these sites are non-functional or that they are cell-context
dependent (Osmanbeyoglu et al., 2012; Whitfield et al., 2012).
Aside from exploring this strategy to build TRNs, we
have introduced TC-YIK as a model to study transcriptional
regulation of pancreatic genes. There is a need for such cell line
models, as the majority of viable post mortem islet cell material
is used for transplants into diabetic patients, thus pancreatic
beta cells for research are difficult to obtain. Moreover, the
isolation of pure beta cell populations, the lack of protocols to
expand them in culture and the number of cells required to carry
out extensive perturbation and chromatin immuno-precipitation
experiments are prohibitive. We have shown by CAGE profiling
that 85% of the beta cell genes identified by the beta cell gene atlas
(Kutlu et al., 2009) are expressed in TC-YIK and that NEUROD1,
LMX1A, PAX6, andRFX6 binding sites in TC-YIK are enriched at
islet cell active enhancer sites. Furthermore, TC-YIK cells express
key transcription factors known to be involved in pancreatic cell
development and differentiation, including NEUROD1, PDX1,
and FOXA2 (Wang et al., 2002; Itkin-Ansari et al., 2005; Guo
et al., 2012). In fact, 33 of the top 42 most TC-YIK enriched TFs
are implicated in pancreatic biology. In addition, 33 homolog TFs
are expressed in developing mouse pancreas. On this account,
we, for the first time, find evidence of ASCL2, HLF, HSF4, IRF6,
IRF8, C11orf9/MYRF, and NPAS3 playing a role in pancreatic
neuroendocrine gene expression and development. The only
two TFs without prior references in the literature or detectable
expression in the FANTOM5 mouse pancreatic samples were
SIX3 and DLX6, respectively. Despite this, DLX6 expression has
previously been reported in earlier pancreatic stages (E12.5 and
E13.5; Gasa et al., 2004). This thorough review shows that the
majority of transcription factors with enriched expression in
TC-YIK have a role in pancreatic development and thus, TC-
YIK is an important cell line model for studying transcriptional
regulation of pancreatic gene expression.
Genome-wide expression profiling of the perturbed samples
by CAGE revealed multiple insights. The majority of TF knock-
downs led to more down-regulated genes than up-regulated
ones, suggesting these TFs primarily work as activators, in
agreement with the arguments of Hurst et al. (2014). From
this logic, we predict HMGA1, NEUROD1, LMX1A, SHOX2,
NROB2, GATA4, RFX6 as likely activators and MNX1 and TBP
as likely repressors. Although there is the possibility that a
predicted activator is in fact a repressor of an activator and
a predicted repressor is an activator of a repressor, we find
that both GATA4 (Rojas et al., 2008) and LMX1A (Andersson
et al., 2006) have direct evidence as transcriptional activators
and MNX1 (William et al., 2003) has been confirmed as a
transcriptional repressor. By incorporating ChIP-seq data we can
verify the roles of TFs directly. For both NEUROD1 and LMX1A
we show that they work as direct transcriptional activators. This
clarifies the role of NEUROD1 as a previous work reported
it as both a transcriptional repressor and activator (Itkin-
Ansari et al., 2005). Integration of the CAGE and ChIP-seq
data clearly shows that >75% of TSS proximal to NEUROD1
are down-regulated in NEUROD1 knock-down (Figure 5A).
In the previous work by Itkin-Ansari et al. the authors used
perturbation (over-expression) alone and assumed SST down-
regulation upon NEUROD1 over-expression indicated it was a
target that was directly transcriptionally repressed; we think
it is more likely that NEUROD1 indirectly antagonizes SST
expression via other pancreatic TFs. This highlights the value of
using both perturbation and ChIP-seq approaches.
In terms of what the application of our strategy to TC-
YIK has told us about pancreatic gene expression, and the
hierarchy of TFs, firstly we have shown that not only enriched
(MNX1, NEUROD1, SHOX2, PAX4, NROB2, HOPX, RFX6,
MLXIPL, GATA4, LMX1A, PAX6, ASCL1) but also non-enriched
factors (ATF5, TAF10, HMGA1, TCF25, TAF9, HMGB2, GTF3A)
contribute to the maintenance of the TC-YIK state. It is thus
important to consider housekeeping TFs, too, when building
cell-specific TRNs since they often work cooperatively with state
specific factors (Ravasi et al., 2010). Our analysis also identified
ISL1 and PROX1 as likely antagonists to the state. It may
be that these antagonists help maintain a stem/progenitor like
state (Wang et al., 2005; Eberhardt et al., 2006). We show that
NEUROD1 and LMX1A are both directly activating multiple
other pancreatic TFs, and that based on our data they do not
directly regulate each other (Figure 5C).
Finally, building cell-type-specific TRNs will require further
work and integration of newer data types. In the case of RFX6
and PAX6 we made no predictions of their direct targets as
there were few peaks bound at promoter regions and there
was no enrichment for perturbed TSS near these peaks. This
could be due to lower quality or less efficient antibodies
used for the two factors, or could reflect lower expression
levels compared to the other factors. Despite this, for all four
factors (including the higher quality NEUROD1 and LMX1A
experiments) the majority of peaks were at putative enhancer
regions. In conclusion, mammalian TRN models will need
to incorporate distal regulatory elements as well, as proximal
elements. To address this issue in the future we will need to use
protocols such as ChIA-PET (Fullwood et al., 2009) and HiC
(Dixon et al., 2012) to link distal elements with the TSS that they
regulate. We believe that such chromatin conformation methods
combined with KD-CAGE and ChIP-seq have the potential to
identify gold standard regulatory events at both promoters and
enhancers, and are key to understanding how each cell type is
wired.
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METHODS
Selection of Transcription Factors
Significantly Enriched in TC-YIK for siRNA
Knock Down
A pre-computed list of TFs with enriched expression in
TC-YIK was downloaded from FANTOM5’s sample browser
SSTAR [direct link: http://fantom.gsc.riken.jp/5/sstar/FF:10589-
108D4, see FANTOM web resource (Lizio et al., 2015)].
Enrichment is based on expression in the sample compared
to the median expression across all samples in the FANTOM5
collection. The enrichment score is defined as log10[(expression
in TC-YIK + 1)/(median expression in FANTOM5 + 1)].
The top 33 genes with enriched expression in TC-YIK were
targeted for siRNA knock-down using stealth siRNAs from
Invitrogen. As a comparison we also targeted a set of 8
non enriched TFs (TAF9, TAF10, ATF5, GTF3A, TCF25, TBP,
HMGA1, HMGB2) that were expressed in TC-YIK at similar
levels. In addition to these TFs, six target genes (INS, CHGA,
GHRL, GCK, GAST, TTR) and five additional target TF genes
where we were unable to find effective siRNAs (ASCL2,
CBFA2T2, CDX2, INSM1, TFAP2A) were also added to the
set. The combined set was used for systematic siRNA KD
in triplicate of one factor at a time followed by qRT-PCR
measurements of the perturbed genes in a Matrix RNAi design
as described in Tomaru et al. (2009). siRNA sequences, knock-
down efficiency and primers used in qRT-PCR are provided in
Supplementary Table 9.
Cell Culture
TC-YIK (Ichimura et al., 1991; Human cervical cancer) cells were
provided by RIKEN BRC (Cell no: RCB0443). Cells were grown
in RPMI1640 (GIBCO), 10% fetal bovine serum (CCB), 1%
penicillin/streptomycin (Wako). TC-YIK cells were incubated at
37◦C in a humidified 5% CO2 incubator.
Genome-wide KD-CAGE
KD experiments followed by CAGE were profiled (see below)
to obtain genome-wide promoter activities. Of the 41 most
enriched TFs that were selected for Matrix RNAi, 15 among the
most perturbed and all 8 non-enriched genes were chosen for
siRNA transfection followed by CAGE. The 15 enriched TFs
targeted for CAGE analysis were selected in a semi-random
fashion that favored TFs that affected insulin expression in the
qRT-PCR results (Figure 2). NEUROD1, DACH1, RFX6, ASCL1,
PAX6, MNX1, HOPX, MLXIPL, LMX1A, SHOX2, GATA4,
and PAX4 knock-down significantly reduced INS transcript
levels. PROX1, NR0B2, and ISL1 were selected based on their
reported roles in pancreatic biology as putative repressors, rather
than their effect on INS levels. Experiments were carried out
in biological triplicate, and scrambled siRNA samples were
prepared as negative control. While the KD method has been
previously described (Vitezic et al., 2010), we used a new
variant of CAGE developed for the Illumina Hiseq 2500 called
nAnT-iCAGE (Murata et al., 2014). Briefly, 5µg of RNA
was used for each sample and libraries were combined in 8-
plex using different barcodes. Tags were de-multiplexed and
mapped to the human genome (hg19) using BWA (Li and
Durbin, 2010), yielding an average of 8.9M mapped counts
per sample (map quality > 20). Expression tables were made
by counting the numbers of mapped tags falling under the
184,827 robust CAGE peaks regions identified in FANTOM5
(Forrest et al., 2014). Differential expressed promoters in
TF knock-downs vs scrambled controls were identified using
edgeR (Robinson et al., 2010) with a significance threshold
of 0.05.
Chromatin Immunoprecipitation Assay
Chromatin was prepared and immunoprecipitation carried out
as described previously (Kubosaki et al., 2009).
List of antibodies used in the ChIP-seq experiments: LMX1A
[LMX1A (C-17), sc-54273X Santa Cruz], NEUROD1 [Neuro D
(G-20), sc-1086X Santa Cruz], RFX6 [RFX6 (S-15), sc-169145X
Santa Cruz], and PAX6 [Anti Pax-6 (C-20], Human (Goat), sc-
7750 X Santa Cruz]. Note to readers, the following antibodies
were also tried but failed in ChIP-seq: [Santa Cruz: Anti ISL1
(K-20) sc-23590X; Anti PAX6 (AD2.38) sc-32766X; Anti Dlx-6
(G-20) sc-18154; Anti HB9 (H-20) sc-22542; Anti DLX6 (C-20)
sc-18155; Anti PDX-1 (A-17) sc-14664 X; and Abnova: Anti ISL1
(H00003670-M05)].
All experiments were carried out as biological duplicates.
Immunoprecipitated and input chromatin samples were
incorporated into 4-plex ChIP-seq libraries using the NEBnext
kit (New England Biolabs). Libraries were labeled with a 6
bp barcode and then pooled to be sequenced on Illumina
HiSeq2000.
Sequencing results were mapped to the human genome (hg19)
using BWA software (Li and Durbin, 2010) providing an average
of ∼180M mapped tags per lane (or, alternatively, ∼45M
per sample), with a mapping rate of >96%. After mapping
we performed peak calling using MACS software (Zhang
et al., 2008) with the recommended default parameter settings
for point binding type of events [mfold=(Refai et al., 2005;
Tompa et al., 2005), bandwidth=300]. We additionally used
Irreproducible Discovery Rate analysis (Li et al., 2011), to
identify reproducible peaks which were used for downstream
analysis.
Motif Enrichment Analysis
We used HOMER software for de-novo motif discovery (Heinz
et al., 2010), as well as to calculate over-representation of known
motifs. Known motifs provided with HOMER (v4.6, 3-29-2014)
were expanded by importing all known NEUROD1, LMX1A,
PAX6, and RFX motifs from SwissRegulon (Pachkov et al.,
2007), JASPAR (Bryne et al., 2008), UniPROBE (Newburger
and Bulyk, 2009), and HOCOMOCO (Kulakovskiy et al.,
2013), into HOMER before carrying out the scan. We used
the function findMotifsGenome.pl to discover motifs in all
reproducible peaks for each factor (genomic regions from hg19)
with the option “–mask” to filter out bindings on repeats.
The target sequences are the regions under the peaks and
the background regions are randomly sampled sequences from
the genome (Hg19) with similar GC content as the target
sequences.
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Gene Ontology Enrichment Analysis
The R Bioconductor GOstats package (Falcon and Gentleman,
2007) was used to obtain gene ontology enrichment scores. For
the ChIP-seq GO analysis was performed on bound TSSs, while
for the CAGE KD experiments, the up- and down-regulated
genes were analyzed separately. For both analyses, all genes
expressed in TC-YIK (>1 TPM) were used as the background.
Data Access
This work is part of the FANTOM5 project. Data
download, genomic tools and co-published manuscripts
have been summarized at http://fantom.gsc.riken.jp/
5/. A ZENBU genome browser view displaying TC-YIK
related expression data can be accessed at this URL:
http://fantom.gsc.riken.jp/zenbu/gLyphs/#config=e3YeqamiJBW
hbPgPq59ubD;loc=hg19::chr14:93349815..93441266 [Reviewer
username: lizio2014-review@riken.jp, password: lizio2014 (note:
if problems after logging in, re-enter the URL and try again.
Password will be removed at publication)]. All sequencing
data used in this study has been deposited to DDBJ Read
Archive (http://www.ddbj.nig.ac.jp/) with accession number
DRA002420 (CAGE data) and DRA002468 (ChIP-seq data).
CAGE expression profiles and enrichment of TFs for TC-YIK
cell line are part of the FANTOM5 main data set. siRNA
perturbations, CAGE-KD, and ChIP-seq experiments were
generated separately for this study. Additional material can
be found at the following URL (http://fantom.gsc.riken.jp/5/
suppl/Lizio_et_al_2014/?cultureKey=&q=5/suppl/Lizio_et_al_
2014 Reviewer username: m.lizio, password: m.lizio).
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Supplementary Figure 1 | Homolog TF genes expressed in mouse
pancreas development series. CAGE expression profiles for 33 of the 42
human homolog TC-YIK-enriched TFs. Only TFs with expression above 1TPM for
at least one developmental stage are shown. On the x-axis are developmental
stages, from E14 until adult state. The y-axis shows expression levels
(normalized TPM).
Supplementary Figure 2 | CAGE KD and qRT-PCR KD comparison. Plots
for 23 transcription factors matched in both CAGE and qRT-PCR. Fold changes
largely agree between technologies. Each dot represents the fold change value
of a target gene among the pool of 52 perturbed genes in the matrix RNAi pilot
study.
Supplementary Figure 3 | HOMER Motif scan summary. Enrichment of
relevant known motif and top novel motif is shown for NEUROD1, LMX1A, PAX6,
and RFX6. Expanded results are available online at (http://fantom.gsc.riken.jp/5/
suppl/Lizio_et_al_2014).
Supplementary Figure 4 | ZENBU genome browser views showing
integration of CAGE and ChIP-seq profiles for LMX1A and NEUROD1. (A)
SYT4 and PLK4 loci have proximal binding of both factors and are affected in both
of the knock-downs. (B) GPD2 and RSRC1 loci have proximal binding of both
factors but are affected in both the knock-downs. (C) PROX1 and ID4 have
proximal binding of both factors but only the knock-down of NEUROD1 affects
expression.
Supplementary Table 1 | Human islet cell enriched transcripts. Detection of
human islet cell enriched transcripts from the beta cell gene atlas (Kutlu et al.,
2009) in TC-YIK.
Supplementary Table 2 | Rat alpha and beta cell enriched transcripts.
Detection of human orthologs of rat alpha and beta cell enriched transcripts from
the beta cell gene atlas (Kutlu et al., 2009) in TC-YIK.
Supplementary Table 3 | Extended main Table 2. TFs enriched in TC-YIK and
their putative function in pancreas.
Supplementary Table 4 | siRNAs and primers used in this study.
Supplementary Table 5 | Matrix RNAi results. Pilot study of systematic
knock-down and qRT-PCR expression measurements for TC-YIK enriched
transcription factors.
Supplementary Table 6 | Affected targets and in/out degree. Summary of
the matrix RNAi study: numbers of affected targets, in- and out-degree and
effects on INS gene.
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Supplementary Table 7 | Promoters perturbed by TF knockdown. List of
promoters detected by edgeR in KD-CAGE sets (p-value of 0.05,
1.5FC).
Supplementary Table 8 | Summary of affected promoters in CAGE KD.
Numbers of differentially expressed promoters in CAGE KD and ratios of affected
TC-YIK enriched promoters.
Supplementary Table 9 | Gene ontology enrichment of perturbed genes.
GO enrichment analysis for CAGE KD differentially expressed promoters (split in
up- and down- regulated).
Supplementary Table 10 | Overlap with open chromatin regions. Overlap of
TC-YIC ChIP-seq peaks and C1-C5 open chromatin regions as defined in
Pasquali et al. (2014).
Supplementary Table 11 | ChIP-seq- CAGE integration. Relationship
between distance from ChIP-seq peak and perturbation in CAGE, for peaks (all,
+motif, −motif).
Supplementary Table 12 | Direct targets of NEUROD1 and LMX1A. TSS that
are down-regulated 1.5-fold, p-value of 0.05 and within 50 kb of a ChIP-seq peak
for the same factor.
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